-
Je něco špatně v tomto záznamu ?
The low expression of circulating microRNA-19a represents an additional mortality risk in stable patients with vascular disease
O. Mayer, J. Seidlerová, V. Černá, A. Kučerová, J. Vaněk, P. Karnosová, J. Bruthans, P. Wohlfahrt, R. Cífková, M. Pešta, J. Filipovský,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- ateroskleróza krev genetika mortalita MeSH
- biologické markery krev MeSH
- časové faktory MeSH
- hodnocení rizik metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikro RNA biosyntéza krev MeSH
- míra přežití trendy MeSH
- následné studie MeSH
- prospektivní studie MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Česká republika MeSH
BACKGROUND: Secondary prevention of atherosclerotic vascular diseases represents a cascade of procedures to reduce the risk of future fatal and non-fatal cardiovascular events. We sought to determine whether the expression of selected microRNAs influenced mortality of stable chronic cardiovascular patients. METHODS: The plasma concentrations of five selected microRNAs (miR-1, miR-19, miR-126, miR-133 and miR-223) were quantified in 826 patients (mean age 65.2 years) with stable vascular disease (6-36 months after acute coronary syndrome, coronary revascularization or first-ever ischemic stroke). All-cause and cardiovascular mortality rates were followed during our prospective study. RESULTS: Low expression (bottom quartile) of all five miRNAs was associated with a significant increase in five-year all-cause death, even when adjusted for conventional risk factors, treatment, raised troponin I and brain natriuretic protein levels [hazard risk ratios (HRRs) were as follows: miR-1, 1.65 (95% CI: 1.16-2.35); miR-19a, 2.27 (95% CI: 1.59-3.23); miR-126, 1.64 (95% CI: 1.15-2.33); miR-133a, 1.46 (95% CI: 1.01-2.12) and miR-223, 2.05 (95% CI: 1.45-2.91)]. Nearly similar results were found if using five-year cardiovascular mortality as the outcome. However, if entering all five miRNAs (along with other covariates) into a single regression model, only low miR-19a remained a significant mortality predictor; and only in patients with coronary artery disease [3.00 (95% CI: 1.77-5.08)], but not in post-stroke patients [1.63 (95% CI: 0.94-2.86)]. CONCLUSIONS: In stable chronic coronary artery disease patients, low miR-19a expression was associated with a substantial increase in mortality risk independently of other conventional cardiovascular risk factors.
Biomedical Center Medical Faculty of Charles University Pilsen Czech Republic
Department of Biology Medical Faculty of Charles University Pilsen Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006366
- 003
- CZ-PrNML
- 005
- 20220606135118.0
- 007
- ta
- 008
- 200511s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijcard.2019.05.008 $2 doi
- 035 __
- $a (PubMed)31085080
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Mayer, Otto $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic. Electronic address: mayero@fnplzen.cz.
- 245 14
- $a The low expression of circulating microRNA-19a represents an additional mortality risk in stable patients with vascular disease / $c O. Mayer, J. Seidlerová, V. Černá, A. Kučerová, J. Vaněk, P. Karnosová, J. Bruthans, P. Wohlfahrt, R. Cífková, M. Pešta, J. Filipovský,
- 520 9_
- $a BACKGROUND: Secondary prevention of atherosclerotic vascular diseases represents a cascade of procedures to reduce the risk of future fatal and non-fatal cardiovascular events. We sought to determine whether the expression of selected microRNAs influenced mortality of stable chronic cardiovascular patients. METHODS: The plasma concentrations of five selected microRNAs (miR-1, miR-19, miR-126, miR-133 and miR-223) were quantified in 826 patients (mean age 65.2 years) with stable vascular disease (6-36 months after acute coronary syndrome, coronary revascularization or first-ever ischemic stroke). All-cause and cardiovascular mortality rates were followed during our prospective study. RESULTS: Low expression (bottom quartile) of all five miRNAs was associated with a significant increase in five-year all-cause death, even when adjusted for conventional risk factors, treatment, raised troponin I and brain natriuretic protein levels [hazard risk ratios (HRRs) were as follows: miR-1, 1.65 (95% CI: 1.16-2.35); miR-19a, 2.27 (95% CI: 1.59-3.23); miR-126, 1.64 (95% CI: 1.15-2.33); miR-133a, 1.46 (95% CI: 1.01-2.12) and miR-223, 2.05 (95% CI: 1.45-2.91)]. Nearly similar results were found if using five-year cardiovascular mortality as the outcome. However, if entering all five miRNAs (along with other covariates) into a single regression model, only low miR-19a remained a significant mortality predictor; and only in patients with coronary artery disease [3.00 (95% CI: 1.77-5.08)], but not in post-stroke patients [1.63 (95% CI: 0.94-2.86)]. CONCLUSIONS: In stable chronic coronary artery disease patients, low miR-19a expression was associated with a substantial increase in mortality risk independently of other conventional cardiovascular risk factors.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ateroskleróza $x krev $x genetika $x mortalita $7 D050197
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x biosyntéza $x krev $7 D035683
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a hodnocení rizik $x metody $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a míra přežití $x trendy $7 D015996
- 650 _2
- $a časové faktory $7 D013997
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Seidlerová, Jitka $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Černá, Václava $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic; Department of Biology, Medical Faculty of Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Kučerová, Alena $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic; Department of Biology, Medical Faculty of Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Vaněk, Jiří $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic. $7 xx0273624
- 700 1_
- $a Karnosová, Petra $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Bruthans, Jan $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Centre for Cardiovascular Prevention, First Faculty of Medicine, Charles, University and Thomayer's Hospital, Prague, Czech Republic.
- 700 1_
- $a Wohlfahrt, Peter $u Centre for Cardiovascular Prevention, First Faculty of Medicine, Charles, University and Thomayer's Hospital, Prague, Czech Republic.
- 700 1_
- $a Cífková, Renata $u Centre for Cardiovascular Prevention, First Faculty of Medicine, Charles, University and Thomayer's Hospital, Prague, Czech Republic.
- 700 1_
- $a Pešta, Martin $u Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic; Department of Biology, Medical Faculty of Charles University, Pilsen, Czech Republic.
- 700 1_
- $a Filipovský, Jan $u 2nd Department of Internal Medicine, Medical Faculty of Charles University and University Hospital, Pilsen, Czech Republic; Biomedical Center, Medical Faculty of Charles University, Pilsen, Czech Republic.
- 773 0_
- $w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 289, č. - (2019), s. 101-106
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31085080 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20220606135116 $b ABA008
- 999 __
- $a ok $b bmc $g 1525224 $s 1096422
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 289 $c - $d 101-106 $e 20190506 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
- LZP __
- $a Pubmed-20200511
